http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Ji Enu Oh ) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
( Dong Gyu Lee ),( Kil Jong Yu ),( Dae Hyeon Cho ),( Ji Enu Oh ),( Chang Wook Jeong ),( Kwang Min Kim ),( Hyoun Soo Lee ),( Jung Won Lee ),( Ik Sung Choi ),( Byung Soo Kwan ),( Sang Goon Shim ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Direct Anti-viral Agent (DAA) has Obtained new indications of treating hepatitis C virus. Various DAA treatment regimens are selected by HCV genotype. Dermatological side effects after sofosbuvir and daclatasvir combination are rare worldwide. Results: We report a case of cutaneous erythema which occurred after treatment of sofoubuvir and daclatasvir for hepatitis C genotype 3 treatment. The 91-year-old male patient visited our clinic complaining of new skin lesions. He was diagnosed with genotype 3a chronic hepatitis C by genetic test. Abdominal ultrasonography shows chronic hepatitis without cirrhosis. Trans Elestography showed F2, which meant that the patient had chronic hepatitis without cirrhosis. Patient was generally good condition. We started treatment daily with sofosbuvir 400mg and daclatasvir 60mg. Then, 56 days later, multiple erythematous scaly patches appeared on the patient’s trunk and pelvis. He had no itching and was kept in good condition. The score of Naranjo ADR probability scale was 7, which indicated probable. The patient’s skin lesions notably improved after the medications were terminated. Finally, the patient obtained SVR 12. Conclusions: In treatment of hepatitis C, the rate of dermatologic side effects by DAA treatment is known around 3-8%, usually. Although in severe cases, there was a case of DRESS. However, in this case, only slight skin patches were observed. The skin side effects by DAA treatment are very rare. And this is the first report of dermatological side effects after sofosbuvir and daclatasvir combination therapy in Korea. More attention needs to be paid to prescribing DAA in the treatment of chronic hepatitis C.
-
( Ik Sung Choi ),( Kil Jong Yu ),( Dae Hyeon Cho ),( Ji Enu Oh ),( Chang Wook Jeong ),( Kwang Min Kim ),( Hyoun Soo Lee ),( Jung Won Lee ),( Dong Kyu Lee ),( Byung Soo Kwan ),( Sang Goon Shim ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: A direct-acting antiviral (DAA) drug is in the spotlight for the treatment of patients with chronic hepatitis C. The combination of sofosbuvir and ribavirin is more effective than the peg IFN and ribavirin in patients with genotype 2 HCV. The aim of this study was to evaluate the treatment efficacy and safety for GT2 HCV patients treated with sofosbuvir and ribavirin in a single center. Methods: The study was performed retrograde from May 2016 to December 2017 in GT2 HCV patients treated with sofosbuvir (400mg) plus ribavirin (800-1200mg; based on body weight) treatment. The primary endpoint was sustained virologic response at 12 weeks (SVR12). The secondary endpoint was the occurrence of side effects during treatment. Results: A total of 95 patients with GT2 HCV infection were enrolled, of which 92 were genotype 2a (96.8%) and 3 were 2b (3.2%). 2 patients were follow up loss, 1 patient discontinued treatment voluntarily. SVR12 was confirmed in 91 of 92 patients (98.91%). 1 patient with failed treatment were combined LC and HCC, HCV RNA was not detected at 4 weeks and 8 weeks after initiation of treatment, but HCV RNA detected at 12 weeks. Liver cirrhosis was diagnosed on the imaging studies or clinical manifestations and 24 patients were included (CTP-A; n=23, C; n=1). SVR12 with cirrhotic patients was 95.83%. The average HCR RNA titer was 2.46x10<sup>6</sup> IU/ml. Hemoglobin decrease (Mean ± SD; 2.95±1.19 g/dl) occurred in 21 patients during treatment and ribavirin dose reduction was required. Conclusions: This study was performed on a small group of patients compared with other studies, but showed that treatment with sofosbuvir and ribavirin was highly effective in patients with GT2 HCV infection. In aspect of safety, there was no serious side effects about treatment although hemoglobin decrease.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
